Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $45,385 | 25 | 98.5% |
| Travel and Lodging | $439.00 | 2 | 1.0% |
| Food and Beverage | $246.47 | 4 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $12,021 | 2 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $10,753 | 11 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $6,784 | 6 | $0 (2023) |
| Merck Sharp & Dohme LLC | $6,730 | 7 | $0 (2024) |
| Ferring Pharmaceuticals AS | $5,863 | 3 | $0 (2017) |
| Genentech, Inc. | $3,920 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,919 | 16 | Regeneron Pharmaceuticals, Inc. ($9,189) |
| 2023 | $2,494 | 3 | Regeneron Pharmaceuticals, Inc. ($1,564) |
| 2022 | $3,920 | 2 | Genentech, Inc. ($3,920) |
| 2021 | $1,085 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($1,085) |
| 2020 | $3,160 | 2 | Bayer HealthCare Pharmaceuticals Inc. ($1,860) |
| 2019 | $2,909 | 3 | Bayer HealthCare Pharmaceuticals Inc. ($2,909) |
| 2018 | $10,721 | 1 | GlaxoSmithKline, LLC. ($10,721) |
| 2017 | $5,863 | 3 | Ferring Pharmaceuticals AS ($5,863) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/14/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,045.00 | General |
| 10/14/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $48.49 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.04 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $26.94 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $289.00 | General |
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $782.00 | General |
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $586.50 | General |
| 08/14/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,564.00 | General |
| 06/24/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $782.00 | General |
| 04/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,955.00 | General |
| 04/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,173.00 | General |
| 04/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $782.00 | General |
| 04/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $782.00 | General |
| 02/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $782.00 | General |
| 11/17/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $782.00 | General |
| 11/03/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $782.00 | General |
| 04/26/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $930.00 | General |
| 05/12/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 05/09/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,120.00 | General |
| 02/09/2021 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Consulting Fee | Cash or cash equivalent | $1,085.00 | General |
| 09/04/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 06/10/2020 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| 11/22/2019 | Bayer HealthCare Pharmaceuticals Inc. | Non-Covered (Drug) | Consulting Fee | Cash or cash equivalent | $1,240.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 6 | 180 | 180 | $8,409 | $1,675 |
| 2021 | 4 | 132 | 132 | $6,375 | $1,307 |
| 2020 | 1 | 12 | 12 | $444.00 | $96.60 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 94375 | Test to measure rate of airflow | Facility | 2022 | 40 | 40 | $2,320 | $462.23 | 19.9% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 55 | 55 | $1,980 | $424.09 | 21.4% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 37 | 37 | $1,961 | $329.35 | 16.8% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 25 | 25 | $1,200 | $260.25 | 21.7% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2022 | 11 | 11 | $528.00 | $114.05 | 21.6% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 12 | 12 | $420.00 | $85.41 | 20.3% |
| 94375 | Respiratory diagnostic testing (flow volume loop) | Facility | 2021 | 40 | 40 | $2,374 | $506.80 | 21.3% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2021 | 49 | 49 | $1,791 | $383.18 | 21.4% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2021 | 24 | 24 | $1,272 | $216.48 | 17.0% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2021 | 19 | 19 | $938.00 | $200.26 | 21.3% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2020 | 12 | 12 | $444.00 | $96.60 | 21.8% |
About Dr. Boyd Thompson, MD
Dr. Boyd Thompson, MD is a Pulmonary Disease healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073503884.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Boyd Thompson, MD has received a total of $46,071 in payments from pharmaceutical and medical device companies, with $15,919 received in 2024. These payments were reported across 31 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($45,385).
As a Medicare-enrolled provider, Thompson has provided services to 324 Medicare beneficiaries, totaling 324 services with total Medicare billing of $3,079. Data is available for 3 years (2020–2022), covering 11 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Location Boston, MA
- Active Since 10/24/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1073503884
Products in Payments
- Non-Covered $2,945
- Non-Covered (Drug) $2,909
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Boston
Bartolome Celli, Md, MD
Pulmonary Disease — Payments: $613,474
Adnan Majid, Md, MD
Pulmonary Disease — Payments: $424,602
Avrum Spira, M.d, M.D
Pulmonary Disease — Payments: $157,114
Dr. Tufik Assad, M.d, M.D
Pulmonary Disease — Payments: $151,341
Dr. Benjamin Medoff, Md, MD
Pulmonary Disease — Payments: $136,103
Kelsey Sack, Md/Phd, MD/PHD
Pulmonary Disease — Payments: $82,500